Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2016) 41 EP379 | DOI: 10.1530/endoabs.41.EP379

ECE2016 Eposter Presentations Clinical case reports - Thyroid/Others (71 abstracts)

Calcific uremic arteriolopathy (Calciphylaxis): case report

Lilit Egshatyan 1, & Lyudmila Rozhinskaya 2


1Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow, Russia; 2FSI ‘Endocrinology Research Center’ of the Ministry Healthcare of the Russian Federation, Moscow, Russia.


Introduction: The calcific uremic arteriolopathy (CUA) is one of the several types of extra-osseous calcification that may occur in patients with end-stage renal disease (ESRD). CUA is a serious disorder characterized by calcification of the arterioles that leads to ischemia and subcutaneous necrosis. The pathogenesis is poorly understood, and the optimal treatment is not known.

Case report: We present the case of a 64-year-old female with ESRD on hemodialysis since 2010, is hypertensive, had a heart attack in 2006. She was referred to our hospital with extensive two ulcers on the left leg with necrotic eschars.

Laboratory investigations showed elevated levels of phosphorus 2.46 mmol/l, calcium 2.73 mmol/l, [Ca]×[P] 6.7 mmol/l, iPTH 2529 pg/ml. Ultrasound revealed multiple enlarged parathyroid glands, DEXA revealed osteopenia. The clinical diagnosis was severe secondary hyperparathyroidism and CUA.

Considering the severity of CUA, was recommended a total parathyroidectomy. However, due to the patient’s cardiovascular status, there were certain contraindications. Initially, we cancelled the warfarin, recommended a hypophosphatic diet, analgesics, intravenous antibiotics, assessment by surgeons for wound care. She started intensive dialysis on a daily: 3-h-sessions with low calcium (1.25 mmol/l) dialysate for 2 weeks, later three times a week, followed by 24 mg of sodium thiosulfate intravenous administration at the end of every session. She was also started on phosphate binders (sevelamer 2400 mg/day) and calcimimetics (cinacalcet 30–60 mg/day) for better control.

Laboratory investigations were done during the treatment – phosphorus 2.14 mmol/l, calcium 2.13 mmol/l, [Ca]×[P] 4.55 mmol/l, iPTH 2086 pg/ml. We added other phosphate binders Almagel for a short period. Six months later, the first CUA lesion was healed, a year later – the second one.

Conclusion: Our case study shows that only a multi-interventional strategy is likely to be more effective in treating CUA in patients on hemodialysis and with several secondary hyperparathyroidisms.

Article tools

My recent searches

No recent searches.

My recently viewed abstracts